...
首页> 外文期刊>The journal of asthma >Association between probiotic supplementation and asthma incidence in infants: a meta-analysis of randomized controlled trials
【24h】

Association between probiotic supplementation and asthma incidence in infants: a meta-analysis of randomized controlled trials

机译:婴幼儿益生菌补充剂和哮喘发病率之间的关联:随机对照试验的荟萃分析

获取原文
获取原文并翻译 | 示例

摘要

Objective: The increased social and economic burdens for asthma in infants make the prevention of asthma a major public health goal. Probiotics may reduce the risk of asthma in infants. However, randomized controlled trials (RCTs) have shown mixed efficacy outcomes. We performed a meta-analysis of RCTs to investigate whether probiotics are associated with a lower asthma incidence in infants. Methods: The PubMed, Cochrane library, and EMBASE databases were systematically searched from the inception dates to August 2018. RCTs comparing the effects of probiotic supplements with a placebo for asthma or wheeze incidence in infants were included. A meta-analysis was performed to calculate risk ratio (RR) and 95% confidence interval (CI) using the Mantel-Haenszel statistical method. Results: A total of 19 randomized trials involving 5157 children fulfilled the inclusion criteria. There was no significant association of probiotics with risk of asthma (RR, 0.94 [95% CI, 0.82-1.09]) or wheeze (RR, 0.97 [95% CI, 0.88-1.06]) compared with placebo. Subgroup analysis by asthma risk showed that probiotics significantly reduced wheeze incidence among infants with atopy disease (RR, 0.61 [95% CI, 0.42-0.90]), but no significant associations were found in the other subgroup analyses by participants receiving the intervention, timing of intervention, prevention regimen, probiotic organism, duration of intervention, and duration of follow-up. Conclusions: The use of probiotic supplementation compared with placebo was not associated with a lower risk of asthma in infants. These findings do not support recommendation to use probiotics in the prevention of asthma in infants.
机译:目的:婴幼儿哮喘的社会和经济负担增加,预防哮喘是一个主要的公共卫生目标。益生菌可能会降低婴儿哮喘的风险。然而,随机对照试验(RCT)显示了混合疗效结果。我们对RCT进行了META分析,以研究益生菌是否与婴儿的哮喘发病率较低。方法:从初始化日期到2018年8月系统地搜查了PubMed,Cochrane图书馆和Embase数据库。RCT将比较益生菌补充剂对婴儿哮喘的安慰率的影响。使用Mantel-Haenszel统计方法来进行META分析以计算风险比(RR)和95%置信区间(CI)。结果:共有19项随机试验涉及5157名儿童履行纳入标准。与安慰剂相比,患有哮喘风险(RR,0.94 [95%CI,0.82-1.09])或喘息(RR,0.97 [95%CI,0.88-1.06])的益生菌的风险没有明显的益生菌。哮喘风险的亚组分析表明,益生菌在具有特性疾病的婴儿(RR,0.61 [95%CI,0.42-0.90])中显着降低了喘息发病率,但在接受干预,时间的参与者的其他亚组分析中没有发现显着的关联。干预,预防方案,益生菌生物,干预持续时间和随访的持续时间。结论:与安慰剂相比,使用益生菌补充与婴儿哮喘风险较低。这些发现不支持在婴儿预防哮喘中使用益生菌的建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号